Stocks Set to Snap Selloff, Dow Eyes Triple-Digit Pop

Investors are reassessing coronavirus-related anxieties

Digital Content Manager
Dec 21, 2021 at 12:02 PM
facebook twitter linkedin

The major benchmarks look set to snap their three-day losing streak today, as investors reassess their anxieties over the fast-spreading omicron variant. The Dow Jones Industrial Average (DJI) is headed for a triple-digit pop, last seen up 368 points, while the S&P 500 Index (SPX) and Nasdaq Composite (IXIC) are also comfortably higher, as Wall Street targets reopening and travel stocks. Meanwhile, earnings reports from Micron Technology (MU) and Nike (NKE) are also creating tailwinds for their respective sectors.  

Continue reading for more on today's market, including: 

  • More on Micron's impressive earnings report
  • Can volatile SAVA stage a year-end comeback?
  • Plus, options traders target GIS; RELI topples key trendline; and ALDX draws slew of bear notes.

midday stats dec 21

General Mills, Inc. (NYSE:GIS) is seeing a surge in options activity today, with 2,028 calls and 1,595 puts across the tape so far -- double the intraday average. Most popular is the January 2022 70-strike call, followed by the 65-strike put in the same series. GIS was last seen down 4.2% at $64.92 after its fiscal second-quarter earnings of 99 cents per share missed analysts' estimates. The equity has fallen back below its 10-day moving average, which helped it hit a Dec. 17 five-year high of $69.68. 

One of the best performers on the Nasdaq today is Reliance Global Group Inc (NASDAQ:RELI). The equity was last seen up 89.1% at $5.77, as investors respond to upbeat subscription data released by the Telecom Regulatory Authority of India (TRAI) for October. RELI hit a Nov. 23 three-year low of $1.83, but has since distanced itself from the level. Plus, the stock is trading back above resistance at its 200-day moving average for the first time since February.

reli chart dec 21

One of the worst stocks on the Nasdaq is Aldeyra Therapeutics Inc (NASDAQ:ALDX). The security was last seen down 51.1% at $3.49, after the company's dry eye disease treatment failed to meet its end goal in a Phase 3 trial. The news sparked no fewer than seven price-target cuts, the lowest coming from Oppenheimer to $10 from $16. ALDX gapped to its lowest level since May 2020 right out of the gate, and is now down 48.8% for the year. 


Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!